Advertise on podcast: Medical News Podcast

Drs. Regillo and Modi review evidence that newer anti-VEGF therapies extend dosing intervals and reduce treatment burden. They discuss port delivery, GA, and chlorhexidine prep.

This episode covers three ESMO trials. AZUR-1 supports organ preservation with dostarlimab in selected patients with mismatch repair deficient or microsatellite instability high rectal cancer. DeLLphi-305 found longer survival with tarlatamab plus durvalumab as maintenance treatment for extensive-stage small-cell lung cancer, with cytokine release syndrome requiring attention. TroFuse-005 found longer survival with sacituzumab tirumotecan than chemotherapy in previously treated advanced or recurrent endometrial cancer, with more severe treatment-related toxicity. The episode reviews the study populations, main results, and limits of each finding.

Drs. Hsu and Dall’Era outline a multipronged strategy for lupus nephritis pairing triple immunosuppression with nephroprotective therapies. They stress the importance of tailored sequencing based on comorbidities to preserve kidney function.

Drs. Yosipovitch and Lio discuss how more patients with atopic dermatitis are achieving sustained control on newer biologics, raising thoughtful questions about when and how to safely reduce or stop treatment. They emphasize that decisions must be individualized, balancing clinical trial data with each patient’s flares, life circumstances, and comfort with adjusting dosing frequency or discontinuing therapy.

This episode covers three studies. A trial found that 2 grams of DHA daily increased a cerebrospinal-fluid marker of brain DHA delivery but did not improve cognition or brain volumes over 24 months. Two trials found that retatrutide reduced sleep-apnea severity in adults with obesity, including those with type 2 diabetes; the drug remains investigational. A global analysis estimated that measles cases and deaths among children under five rose between 2019 and 2023, alongside a decline in first-dose vaccine coverage.

This episode covers three studies. In CONNECT, continuous glucose monitoring improved A1C and time in range in adults with type 2 diabetes who were not using insulin. A meta-analysis found cardiovascular benefits from intensive blood pressure treatment in people with and without CKD, with more sustained declines in estimated kidney function but no clear difference in kidney failure. A small ovarian tissue study identified age-related protein changes after menopause. Its implications for women’s health remain uncertain.

This episode reviews three observational studies. In hospitalized patients with alcohol withdrawal, phenobarbital was not associated with shorter stays or less mechanical ventilation than diazepam, although self-directed discharge was less frequent. Higher p-tau217 was associated with later cognitive impairment, particularly among APOE-ε4 carriers, a finding the authors say may help identify higher-risk people and recruit for trials. In CARDIA, cannabis exposure was associated with more fragmented objective sleep, despite no association with perceived sleep quality.

Drs. Dall’Era and Hsu outline the shift to triple immunosuppressive combination therapy for lupus nephritis. They emphasize aligning B-cell–targeted and CNI-based regimens with renal severity, extrarenal disease, and flare risk.

This episode reviews randomized-trial analyses of antidepressant-related QTc changes and early cardiovascular events; an observational study of buprenorphine initiation during concurrent alcohol and opioid withdrawal; and a target-trial emulation examining renal outcomes with SGLT2 inhibitors and GLP-1 receptor agonists according to albuminuria status.

Drs. Martinez and Montesi discuss how to personalize treatment for ILD, particularly IPF. They explain that current personalization is largely driven by side effects, insurance constraints, and patient preferences, emphasizing the need to move toward biomarker- and imaging-guided, pathway-based therapies and innovative clinical trial designs (eg, cohort enrichment and platform trials) similar to oncology.

Drs. Lio and Yosipovitch discuss that while biologic therapy has greatly improved atopic dermatitis control, many patients still struggle with residual itch, sleep disruption, and intermittent flares that impact daily life. They explain how layering proactive topical treatments, over-the-counter skincare, antipruritic measures, and behavioral strategies onto biologics can preempt flares, relieve itch, and significantly improve quality of life.

This episode covers the Jehovah’s Witness policy change making acceptance of donor blood components an individual conscience decision; a study associating short oral steroid courses with serious adverse events in adults with type 2 diabetes; and a scoping review documenting sex differences in medical treatment.

This episode reviews a randomized phase 3 trial suggesting that loberamisal may improve functional recovery following acute ischemic stroke; a SELECT trial analysis examining the efficacy and safety of semaglutide across different levels of frailty; and a CDC investigation of deaths and serious adverse events following ceftriaxone injections that highlights how severe anaphylaxis can occur without classic skin findings.

Drs. Scarfò and Ghia discuss how CLL creates a delicate balance between blood clots and bleeding, a challenge made more complex by BTK inhibitors and common comorbidities in older patients. They explore how careful risk assessment, thoughtful use of anticoagulants, and close patient communication are essential to keep treatment both effective and safe.

This episode reviews updated AAP recommendations for RSV prevention in infants and high-risk children entering a second RSV season, phase 3 data suggesting TP53 mutation status may help identify patients with EGFR-mutated advanced non–small cell lung cancer who benefit from adding chemotherapy to osimertinib, and results from two phase 3 trials showing that the IL-33–targeting biologic tozorakimab reduced COPD exacerbations in patients who remained at risk despite standard inhaled therapy.